Want to take the Stockholm3 test?

Prostate cancer is the second most common cancer in the world, 1.4 million men are diagnosed yearly. Early detection is the key to successful treatment. Currently, about 200 caregivers around Sweden offer the Stockholm3 test. Find your nearest healthcare provider here.


A3P Biomedical’s lead product is Stockholm3, a blood test that combines protein markers, genetic markers and clinical data with an advanced algorithm in order to detect aggressive prostate cancer at an early stage.

  • 100 %

    More cases of aggressive cancers found

  • 50 %

    Fewer unnecessary biopsies

  • 17-28 %

    Reduced healthcare costs

  • 75000

    Participants in clinical studies

Annual general meeting 2021

The annual general meeting 2021 took place on 22 June, 2021.

History and development

A3P Biomedical AB was founded in 2020. The development of the company’s leading product Stockholm3, a clinically and commercially validated blood test for early detection of aggressive prostate cancer, began much earlier. Several leading healthcare providers in Sweden and Norway have replaced PSA with Stockholm3. Synlab, Europe’s largest laboratory chain, has started a roll-out in Europe.